http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html si-local-file:///var/storage/secattach/20260611/26635615.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html Thu, 11 Jun 2026 16:05:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html si-local-file:///var/storage/secattach/20260611/26635615.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html Thu, 11 Jun 2026 16:05:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html si-local-file:///var/storage/secattach/20260611/26635615.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26635615.html Thu, 11 Jun 2026 16:05:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html si-local-file:///var/storage/secattach/20260611/26635494.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html Thu, 11 Jun 2026 16:01:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html si-local-file:///var/storage/secattach/20260611/26635494.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html Thu, 11 Jun 2026 16:01:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html si-local-file:///var/storage/secattach/20260611/26635494.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jun+11/26635494.html Thu, 11 Jun 2026 16:01:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html <div class="xn-content"> <p class="prntac"><b><i>Conference to be held in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, CA</location>, USA – <chron>June 22-25, 2026</chron></i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <b><span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span></b> (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming <span>BIO International Convention</span>, to be held on <chron>June 22-25</chron>, in <span>San Diego, USA</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Evogene+to+Present+Its+Pharma+Division+Achievements+at+the+BIO+International+Convention/26620055.html Tue, 09 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/FDA/Evogene+completes+phase+1+trial+of+bacterial+cancer+treatment+BMC128/26587215.html <p>Evogene Ltd. (NASDAQ: EVGN) announced completion of a phase 1 clinical study of BMC128, a live bacterial product developed by subsidiary Biomica, in combination with cancer immunotherapy drug nivolumab.</p> <p>The open-label study enrolled 11 patients with advanced solid tumors including melanoma, renal cell carcinoma, and non-small cell lung cancer who had previously progressed on anti-PD-1 immunotherapy. The treatment included two weeks of BMC128 alone, followed by 16 weeks of combination therapy with BMC128 and nivolumab.</p> <p>The study met its primary endpoint of safety and tolerability, with no dose-limiting toxicities observed. Five of 11 patients achieved stable disease beyond the 16-week combination period. http://www.streetinsider.com/FDA/Evogene+completes+phase+1+trial+of+bacterial+cancer+treatment+BMC128/26587215.html Tue, 02 Jun 2026 07:00:48 -0400 EVGN O.05114039 http://www.streetinsider.com/FDA/Evogene+completes+phase+1+trial+of+bacterial+cancer+treatment+BMC128/26587215.html <p>Evogene Ltd. (NASDAQ: EVGN) announced completion of a phase 1 clinical study of BMC128, a live bacterial product developed by subsidiary Biomica, in combination with cancer immunotherapy drug nivolumab.</p> <p>The open-label study enrolled 11 patients with advanced solid tumors including melanoma, renal cell carcinoma, and non-small cell lung cancer who had previously progressed on anti-PD-1 immunotherapy. The treatment included two weeks of BMC128 alone, followed by 16 weeks of combination therapy with BMC128 and nivolumab.</p> <p>The study met its primary endpoint of safety and tolerability, with no dose-limiting toxicities observed. Five of 11 patients achieved stable disease beyond the 16-week combination period. http://www.streetinsider.com/FDA/Evogene+completes+phase+1+trial+of+bacterial+cancer+treatment+BMC128/26587215.html Tue, 02 Jun 2026 07:00:48 -0400 EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/Press+Releases/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html <div class="xn-content"> <p class="prntac">Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity</p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> ("<span value="TelAviv:EVGN" idsrc="xmltag.org" >Evogene</span>") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, <span>Biomica Ltd.</span>, in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small http://www.streetinsider.com/PRNewswire/Evogene+Announces+Successful+Completion+of+Phase+1+Clinical+Study+of+BMC128%2C+a+Rationally+Designed+Live+Bacterial+Product%2C+in+Combination+with+Nivolumab+by+its+Subsidiary+Biomica/26587188.html Tue, 02 Jun 2026 07:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html <p> <b>Q1 2026 Key Milestones Achieved &amp; Highlights:</b> </p><ul class="bwlistdisc"> <li> Closed new $13.0 million asset-level credit facility and operating line of credit with Farm Credit Canada (“FCC”), and paid down $12.0 million of corporate-level debt </li> <li> Closed second tranche of previously announced non-brokered private placement for gross proceeds of approximately $1.9 million </li> <li> Pacific Coast Renewables (“PCR”) RNG Expansion project passed a key regulatory milestone by receiving approval to construct an anerobic digester at the facility. </li> <li> Strong corporate RNG production at Fraser Valley Biogas (“FVB”) and Grow The Energy Circle (“GrowTEC”) facilities </li> <li> FVB 20-Year Offtake Agreement with FortisBC Energy Inc. now in effect </li> </ul> <p> VANCOUVER, British Columbia--(BUSINESS http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html Thu, 28 May 2026 17:57:00 -0400 A.11942376 A.37633838 A.50113893 EVGIF EVGN O.00158908 O.00790772 O.06029410 O.52416071 http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html <p> <b>Q1 2026 Key Milestones Achieved &amp; Highlights:</b> </p><ul class="bwlistdisc"> <li> Closed new $13.0 million asset-level credit facility and operating line of credit with Farm Credit Canada (“FCC”), and paid down $12.0 million of corporate-level debt </li> <li> Closed second tranche of previously announced non-brokered private placement for gross proceeds of approximately $1.9 million </li> <li> Pacific Coast Renewables (“PCR”) RNG Expansion project passed a key regulatory milestone by receiving approval to construct an anerobic digester at the facility. </li> <li> Strong corporate RNG production at Fraser Valley Biogas (“FVB”) and Grow The Energy Circle (“GrowTEC”) facilities </li> <li> FVB 20-Year Offtake Agreement with FortisBC Energy Inc. now in effect </li> </ul> <p> VANCOUVER, British Columbia--(BUSINESS http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html Thu, 28 May 2026 17:57:00 -0400 A.11942376 A.37633838 A.50113893 EVGIF EVGN O.00158908 O.00790772 O.06029410 O.52416071 http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html <p> <b>Q1 2026 Key Milestones Achieved &amp; Highlights:</b> </p><ul class="bwlistdisc"> <li> Closed new $13.0 million asset-level credit facility and operating line of credit with Farm Credit Canada (“FCC”), and paid down $12.0 million of corporate-level debt </li> <li> Closed second tranche of previously announced non-brokered private placement for gross proceeds of approximately $1.9 million </li> <li> Pacific Coast Renewables (“PCR”) RNG Expansion project passed a key regulatory milestone by receiving approval to construct an anerobic digester at the facility. </li> <li> Strong corporate RNG production at Fraser Valley Biogas (“FVB”) and Grow The Energy Circle (“GrowTEC”) facilities </li> <li> FVB 20-Year Offtake Agreement with FortisBC Energy Inc. now in effect </li> </ul> <p> VANCOUVER, British Columbia--(BUSINESS http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html Thu, 28 May 2026 17:57:00 -0400 A.11942376 A.37633838 A.50113893 EVGIF EVGN O.00158908 O.00790772 O.06029410 O.52416071 http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html <p> <b>Q1 2026 Key Milestones Achieved &amp; Highlights:</b> </p><ul class="bwlistdisc"> <li> Closed new $13.0 million asset-level credit facility and operating line of credit with Farm Credit Canada (“FCC”), and paid down $12.0 million of corporate-level debt </li> <li> Closed second tranche of previously announced non-brokered private placement for gross proceeds of approximately $1.9 million </li> <li> Pacific Coast Renewables (“PCR”) RNG Expansion project passed a key regulatory milestone by receiving approval to construct an anerobic digester at the facility. </li> <li> Strong corporate RNG production at Fraser Valley Biogas (“FVB”) and Grow The Energy Circle (“GrowTEC”) facilities </li> <li> FVB 20-Year Offtake Agreement with FortisBC Energy Inc. now in effect </li> </ul> <p> VANCOUVER, British Columbia--(BUSINESS http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html Thu, 28 May 2026 17:57:00 -0400 A.11942376 A.37633838 A.50113893 EVGIF EVGN O.00158908 O.00790772 O.06029410 O.52416071 http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html <p> <b>Q1 2026 Key Milestones Achieved &amp; Highlights:</b> </p><ul class="bwlistdisc"> <li> Closed new $13.0 million asset-level credit facility and operating line of credit with Farm Credit Canada (“FCC”), and paid down $12.0 million of corporate-level debt </li> <li> Closed second tranche of previously announced non-brokered private placement for gross proceeds of approximately $1.9 million </li> <li> Pacific Coast Renewables (“PCR”) RNG Expansion project passed a key regulatory milestone by receiving approval to construct an anerobic digester at the facility. </li> <li> Strong corporate RNG production at Fraser Valley Biogas (“FVB”) and Grow The Energy Circle (“GrowTEC”) facilities </li> <li> FVB 20-Year Offtake Agreement with FortisBC Energy Inc. now in effect </li> </ul> <p> VANCOUVER, British Columbia--(BUSINESS http://www.streetinsider.com/Press+Releases/EverGen+Infrastructure+Reports+Q1+2026+Results/26569058.html Thu, 28 May 2026 17:57:00 -0400 A.11942376 A.37633838 A.50113893 EVGIF EVGN O.00158908 O.00790772 O.06029410 O.52416071